A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Public ClinicalTrials.gov record NCT04569747. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
20-347 NCT Number Title A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer. The study drugs involved in this study are: * A combination of trastuzumab and pertuzumab given as an injection under the skin (PHESGO) * Hormonal (endocrine) Treatment
Study identification
- NCT ID
- NCT04569747
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 393 participants
Conditions and interventions
Conditions
Interventions
- Pertuzumab+TRASTUZUMAB Combination Product
- ADJUVANT ENDOCRINE THERAPY Drug
Combination Product · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 11, 2021 (Actual)
- Primary completion
- Mar 23, 2029 (Estimated)
- Completion
- Sep 1, 2032 (Estimated)
- Last update posted
- Oct 6, 2026
2021 – 2032
United States locations
- U.S. sites
- 32
- U.S. states
- 13
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stamford Hospital | Stamford | Connecticut | 06904 | — |
| University of Miami- Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Winship Cancer Institute at Emory University Hospital Midtown | Atlanta | Georgia | 30308 | — |
| Emory University - Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Winship Cancer Institute at Emory Saint Joseph's Hospital | Atlanta | Georgia | 30342 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Indiana University Health Schwarz Cancer Center | Indianapolis | Indiana | 46032 | — |
| Indiana University Health - Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| Indiana University Sidney and Lois Eskenazi Hospital | Indianapolis | Indiana | 46202 | — |
| Eastern Maine Medical Center (Northern Light) | Brewer | Maine | 04412 | — |
| Dana Farber Cancer Institite | Boston | Massachusetts | 02115 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana-Farber Brigham Cancer Center - Foxborough | Foxborough | Massachusetts | 02035 | — |
| Cape Cod Healthcare Center | Hyannis | Massachusetts | 02601 | — |
| Dana-Farber at Milford | Milford | Massachusetts | 01757 | — |
| Dana-Farber at South Shore Hospital | Weymouth | Massachusetts | 02190 | — |
| Dana-Farber Cancer Insitute at Londonderry Hospital | Londonderry | New Hampshire | 03053 | — |
| New York University Langone Hospital -Brooklyn | Brooklyn | New York | 11220 | — |
| New York University Langone Hospital - Long Island | Mineola | New York | 11501 | — |
| New York University Langone Health | New York | New York | 10016 | — |
| UNC Rex Hematology Oncology Associated - Cary | Cary | North Carolina | 27518 | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| UNC Rex Hematology Oncology Associates of Garner | Garner | North Carolina | 27529 | — |
| UNC Rex Cancer Center | Raleigh | North Carolina | 27607 | — |
| UNC Rex Cancer Center at Wakefield | Raleigh | North Carolina | 27614 | — |
| The Christ Hospital | Cincinnati | Ohio | 45219 | — |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| Greco-Hainsworth Centers for Research/Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37203 | — |
| Baylor College of Medicine Medical Center | Houston | Texas | 77030 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04569747, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 6, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04569747 live on ClinicalTrials.gov.